The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
22 | 26 | 36 | 31 |
Growth
|
31 | 55 | 27 | 57 |
Safety
|
100 | 100 | 59 | 59 |
Sentiment
|
57 | 34 | 51 | 21 |
|
24 | 24 | 42 | 21 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
78 | 75 | 100 | 88 |
Opinions Change
|
100 | 50 | 50 | 50 |
Pro Holdings
|
n/a | 46 | 21 | 10 |
Market Pulse
|
7 | 7 | 28 | 24 |
Sentiment
|
57 | 34 | 51 | 21 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
22 | 26 | 36 | 31 |
Growth
|
31 | 55 | 27 | 57 |
|
100 | 100 | 59 | 59 |
Combined
|
56 | 56 | 88 | 88 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
36 | 36 | 36 | 36 |
Price vs. Earnings (P/E)
|
1 | 1 | 11 | 8 |
Price vs. Book (P/B)
|
81 | 79 | 78 | 74 |
Dividend Yield
|
1 | 1 | 1 | 1 |
Value
|
22 | 26 | 36 | 31 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
1 | 8 | 4 | 25 |
Profit Growth
|
77 | 63 | 42 | 89 |
Capital Growth
|
67 | 69 | 69 | 91 |
Stock Returns
|
15 | 61 | 41 | 13 |
Growth
|
31 | 55 | 27 | 57 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
100 | 100 | 100 | 100 |
Refinancing
|
87 | 96 | 97 | 87 |
Liquidity
|
1 | 1 | 17 | 17 |
|
100 | 100 | 59 | 59 |
Discover high‑ranked alternatives to Ikena Oncology and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.